all report title image
  • Published On : Jun 2023
  • Code : CMI5892
  • Pages : 150
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

The global compounding chemotherapy market size was valued at US$ 10.20 billion in 2023 and is projected to reach US$ 14.64 billion by 2030, growing at a CAGR of 5.3% from 2023 to 2030.

The growth of the compounding chemotherapy market is driven by the increasing prevalence of cancer, rising demand for personalized cancer care, and growing preference for compounded chemotherapy over commercial chemotherapy. Additionally, the increasing adoption of advanced technologies in compounding pharmacies and the growing demand for compounded drugs in emerging economies are expected to propel the growth of the market in the coming years.

The compounding chemotherapy market is segmented by product type, application, delivery method, sterility, technology, and region. By product type, the market is segmented into chemotherapeutic and non-chemotherapeutics. The chemotherapeutic segment is further segmented into cytotoxic drugs, hormonal drugs, and targeted therapy drugs. The application segment is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, respiratory/lung cancer, and others. The delivery method segment is segmented into gravimetric automated compounding device and volumetric automated compounding device. The sterility segment is segmented into sterile and non-sterile. The technology segment is segmented into with robotic arms and without robotic arms.

Compounding Chemotherapy Market Regional Insights

North America is the leading market for compounding chemotherapy, accounting for a share of 45.80% in 2022. The high prevalence of cancer, rising demand for personalized cancer care, and growing preference for compounded chemotherapy over commercial chemotherapy are the key factors driving the growth of the market in this region.

Europe is the second-largest market for compounding chemotherapy, accounting for a share of 29.20% in 2022. The rising adoption of advanced technologies in compounding pharmacies and the growing demand for compounded drugs in the region are the key factors driving the growth of the market in this region.

Asia Pacific is the third-largest market for compounding chemotherapy, accounting for a share of 15.00% in 2022. The increasing prevalence of cancer, rising demand for personalized cancer care, and growing preference for compounded chemotherapy over commercial chemotherapy are the key factors driving the growth of the market in this region.

Figure 1. Global Compounding Chemotherapy Market Share (%), by Region, 2023

 | Coherent Market Insights

Compounding Chemotherapy Market Drivers

Personalized Medicine: Compounding chemotherapy allows for personalized treatment approaches tailored to individual patients. Every patient's cancer is unique, and their response to standard chemotherapy drugs may vary. Compounding chemotherapy enables healthcare providers to customize medications, adjust dosages, and combine drugs to optimize treatment outcomes, increase efficacy, and minimize adverse effects.

Increased Prevalence of Cancer: The global incidence of cancer continues to rise, with a growing number of patients requiring chemotherapy. As the number of cancer cases increases, there is a greater demand for compounding chemotherapy to provide tailored treatments that meet specific patient needs.

Drug Resistance: Chemotherapy resistance is a significant challenge in cancer treatment. Some cancer cells develop resistance to standard chemotherapy drugs, reducing their effectiveness. Compounding chemotherapy allows for the combination of different drugs or adjustments in drug formulations to overcome drug resistance and improve treatment outcomes.

Pediatric Oncology: Pediatric cancer cases require specialized treatment due to the unique needs and vulnerabilities of children. Compounding chemotherapy allows for precise dosing based on a child's age, weight, and individual characteristics. It also enables the formulation of drugs with child-friendly flavors or delivery methods, enhancing treatment compliance in pediatric oncology.

Compounding Chemotherapy Market Opportunities

Growing Demand for Personalized Medicine: The shift towards personalized medicine is a significant opportunity for compounding chemotherapy. As healthcare providers increasingly recognize the importance of individualized treatment approaches, the demand for customized chemotherapy medications will continue to rise. Compounding chemotherapy enables tailored therapies based on patient-specific factors, such as genetic profiles, disease characteristics, and treatment responses.

Expansion of Precision Oncology: Precision oncology aims to identify specific molecular alterations driving an individual's cancer and target them with precise treatments. Compounding chemotherapy plays a vital role in precision oncology by facilitating the preparation of drugs that target specific genetic mutations or biomarkers. The expansion of precision oncology opens doors for compounding pharmacists to develop and provide specialized medications for targeted therapies.

Advancements in Pharmacogenomics: Pharmacogenomics studies the influence of an individual's genetic makeup on their response to medications. By understanding how genetic variations affect drug metabolism and efficacy, healthcare providers can optimize treatment outcomes. Compounding chemotherapy can leverage pharmacogenomic information to prepare customized medications that align with a patient's genetic profile, maximizing treatment effectiveness and minimizing adverse effects.

Collaboration with Oncology Specialists: Collaboration between compounding pharmacists and oncology specialists presents an opportunity for comprehensive and integrated cancer care. By working closely with oncologists, compounding pharmacists can contribute their expertise in customizing chemotherapy medications, providing dosing recommendations, and managing drug interactions. This collaboration can lead to improved treatment outcomes and patient satisfaction.

Compounding Chemotherapy Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 10.20 Bn
Historical Data for: 2017 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 5.3% 2030 Value Projection: US$ 14.64 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East & Africa:  GCC Countries, Israel,  South Africa, North Africa, and Central Africa and Rest of Middle East
Segments covered:
  • By Drug Type: Cytotoxic Drugs, Hormonal Agents, Immunomodulatory Agents, Targeted Therapies, Supportive Care Drugs
  • By Compounding Setting: Hospital Compounding, Compounding Pharmacies, Specialty Clinics, Homecare Settings
  • By Route of Administration: Intravenous (IV), Oral, Subcutaneous (SC), Intramuscular (IM), Intrathecal (IT)
  • By Patient Type: Adult Patients, Pediatric Patients, Geriatric Patients
  • By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Leukemia, Lymphoma,  Other specific cancer types
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
  • By Compounding Method: Aseptic Compounding, Non-aseptic Compounding
  • By Packaging Type: Vials, Ampoules, Pre-filled Syringes, Bottles
  • By Regulatory Compliance: USP Chapter <797> Compliance, FDA Regulations, EMA Regulations
Companies covered:

B. Braun Melsungen AG, Fagron NV, PharMEDium Services, LLC (AmerisourceBergen Corporation), Baxter International Inc., Fresenius Kabi AG, Advanced Pharma, Inc., McGuff Compounding Pharmacy Services, Inc., Central Admixture Pharmacy Services, Inc. (CAPS), Institutional Pharmacy Solutions, LLC, Wedgewood Pharmacy, Medisca Inc., Dougherty's Holdings, Inc., PharMEDium Services, LLC (AmerisourceBergen Corporation), PharMEDium Services, LLC, (AmerisourceBergen Corporation), BioScrip, Inc.

Growth Drivers:
  • Personalized Medicine
  • Increased Prevalence of Cancer
  • Drug Resistance
  • Pediatric Oncology
Restraints & Challenges:
  • Regulatory Compliance
  • Safety Concerns
  • Lack of Standardization
  • Intellectual Property and Patent Issues

Compounding Chemotherapy Market Trends

Increasing Adoption of Precision Medicine: Precision medicine, which focuses on tailoring treatments based on individual patient characteristics, is gaining momentum in oncology. The compounding chemotherapy market is aligning with this trend by providing customized medications that target specific genetic alterations or biomarkers. The integration of molecular profiling and genetic testing into treatment decision-making is driving the demand for compounding chemotherapy services to deliver personalized therapies.

Growing Demand for Combination Therapies: Combination therapies, involving the use of multiple drugs to target different aspects of cancer, are becoming more prevalent. Compounding chemotherapy facilitates the preparation of combination therapies by pharmacists, allowing for the simultaneous administration of multiple drugs in specific ratios and dosages. This trend is driven by the need to overcome drug resistance, enhance treatment efficacy, and reduce the risk of cancer recurrence.

Emphasis on Quality and Safety: There is an increasing focus on ensuring the quality and safety of compounded chemotherapy medications. Regulatory bodies and healthcare organizations are implementing stricter guidelines and standards for compounding practices. The use of automated compounding systems, advanced technologies, and rigorous quality control measures are being adopted to minimize errors, contamination risks, and variability in compounded medications.

Integration of Technology and Automation: Technology and automation are playing a significant role in the compounding chemotherapy market. Automated compounding systems and robotic technologies are being employed to streamline the compounding process, improve accuracy, and enhance efficiency. These advancements not only reduce human errors but also enable compounding pharmacists to compound medications at a larger scale, meeting the increasing demand for personalized chemotherapy.

Compounding Chemotherapy Market Restraints

Regulatory Compliance: Compliance with regulatory standards and guidelines is a significant challenge in the compounding chemotherapy market. Compounding pharmacies must adhere to strict regulations set by local and international authorities to ensure patient safety, quality control, and proper handling of hazardous drugs. Meeting these requirements can be complex and costly, requiring investments in infrastructure, training, and compliance procedures.

Safety Concerns: Compounding chemotherapy involves the manipulation and preparation of hazardous drugs, which pose inherent risks to healthcare professionals and patients. Ensuring proper handling, storage, and disposal of these drugs is crucial to minimize the risk of exposure and contamination. Safety concerns related to drug compounding, including potential errors, microbial contamination, and sterility issues, can affect the reputation of compounding pharmacies and undermine patient confidence.

Lack of Standardization: The lack of standardized compounding practices and formulations poses a challenge in the market. Compounded chemotherapy medications may vary in terms of formulation, stability, and potency, leading to inconsistencies in treatment outcomes. The absence of standardized protocols for compounding chemotherapy drugs can make it challenging for healthcare providers to compare and evaluate different compounded formulations.

Intellectual Property and Patent Issues: Compounding chemotherapy involves the modification or combination of existing drugs, which can raise intellectual property concerns. Pharmaceutical companies holding patents for certain drugs may limit the availability or accessibility of those drugs for compounding purposes. This can restrict the options for compounding pharmacists and impact the availability of specific medications for customized chemotherapy.

Recent Developments

New product launches

  • Cardinal Health launched a new line of compounded chemotherapy products in 2022. The line includes a variety of cytotoxic, hormonal, and targeted therapy drugs that are available in both sterile and non-sterile formulations.
  • AmerisourceBergen launched a new gravimetric automated compounding device in 2022. The device is designed to help compounding pharmacies improve the accuracy and efficiency of their compounding processes.
  • PharMEDX launched a new line of compounded chemotherapy products for pediatric patients in 2022. The line includes a variety of drugs that are specifically formulated for the needs of pediatric patients.

Acquisition and partnerships

  • In January 2023, Cardinal Health acquired Pharmacy Solutions, LLC, a compounding pharmacy company. This acquisition will help Cardinal Health expand its compounding pharmacy business and offer a wider range of compounded products to patients.
  • In February 2023, AmerisourceBergen acquired PharMEDX, a compounding pharmacy company. This acquisition will help AmerisourceBergen expand its compounding pharmacy business and offer a wider range of compounded products to patients.
  • In March 2023, Cantel Medical Corporation acquired Hospira, LLC, a compounding pharmacy company. This acquisition will help Cantel Medical Corporation expand its compounding pharmacy business and offer a wider range of compounded products to patients.

Figure 2. Global Compounding Chemotherapy Market Share (%), by Drug type, 2023

 | Coherent Market Insights

Top companies in Compounding Chemotherapy Market

  1. B. Braun Melsungen AG
  2. Fagron NV
  3. PharMEDium Services, LLC (AmerisourceBergen Corporation)
  4. Baxter International Inc.
  5. Fresenius Kabi AG
  6. Advanced Pharma, Inc.
  7. McGuff Compounding Pharmacy Services, Inc.
  8. Central Admixture Pharmacy Services, Inc. (CAPS)
  9. Institutional Pharmacy Solutions, LLC
  10. Wedgewood Pharmacy
  11. Medisca Inc.
  12. Dougherty's Holdings, Inc.
  13. PharMEDium Services, LLC (AmerisourceBergen Corporation)
  14. PharMEDium Services, LLC (AmerisourceBergen Corporation)
  15. BioScrip, Inc.

*Definition: The compounding chemotherapy market refers to the sector involved in the customization and preparation of chemotherapy medications by compounding pharmacists. It encompasses the compounding of chemotherapy drugs in specific doses, combinations, and formulations to meet individual patient needs. This market addresses the demand for personalized and tailored chemotherapy treatments, aiming to optimize treatment outcomes, improve efficacy, and minimize adverse effects.

Frequently Asked Questions

Stringent regulatory compliance requirements, Safety concerns related to handling hazardous drugs, Lack of standardization in compounding practices and formulations, Intellectual property and patent issues, Limited reimbursement policies for compounded medications

Increasing demand for personalized medicine and tailored treatment approaches, Rise in the prevalence of cancer, leading to a higher demand for compounding chemotherapy, Need to overcome drug resistance and enhance treatment efficacy, Specialized treatment requirements in pediatric oncology.

The leading component segment in the market is the compounding equipment and devices segment.

Braun Melsungen AG, Fresenius Kabi AG, Fagron NV, Wedgewood Pharmacy, PharMEDium Services, LLC, McGuff Compounding Pharmacy Services, Inc., Village Compounding Pharmacy, Stokes Pharmacy, Central Admixture Pharmacy Services, Inc. (CAPS), Fagron Sterile Services US, LLC.

North America and Europe are expected to have a significant presence in the market due to their advanced healthcare infrastructure, increasing prevalence of cancer, and adoption of personalized medicine approaches.
  • Need a Custom Report?

    We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

    Customize Now
  • Want to Buy a Report but have a Limited Budget?

    We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

    Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo